Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

Share Price is delayed by 15 minutes
Get Live Data
526.00    2.00 (0.38%)
Bid:
524.00
Ask:
526.00
Spread: 2.00 (0.382%)
Market Cap: £870.35m
OCI Live PriceLast checked at - London Stock Exchange

Intraday Oakley Share Chart

Update from QuotedData

12 Feb 2026 12:05

RNS Number : 8096S
Oakley Capital Investments Limited
12 February 2026
 

Oakley Capital Investments - Update from QuotedData

12 February 2026

Southern Europe strategy plays to strengths

Oakley Capital's recent investment activity highlights its ability to leverage its strengths in Southern Europe, where many industries are ripe for digital transformation and private equity involvement is low.

A key example is Oakley's investment in Spanish legal tech firm vLex. After investing in 2022, Oakley helped vLex develop its artificial intelligence (AI) platform and expand into the US. The company was sold for $1bn, becoming one of the few Spanish tech start-ups to reach unicorn status. This deal delivered Oakley a gross return in excess of 6 times its investment and an IRR >80%.

Oakley Capital Investments (OCI) offers shareholders access to private equity opportunities sourced by its manager Oakley. With signs of recovery in Europe's private markets, OCI's 27.9% discount to NAV looks appealing.

Full Research:

https://quoteddata.com/research/oakley-capital-investments-southern-europe-strategy-plays-to-strengths-qd/

This research is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

NB: Marten & Co was paid to produce this note Oakley Capital Investments Limited, and it is for information purposes only. It is not intended to encourage the reader to deal in the security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which is authorised and regulated by the Financial Conduct Authority. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of the Financial Conduct Authority.

QUOTEDDATA50 Gresham Street | London EC2V 7AYTel: +44 (0) 20 3691 9430

www.quoteddata.com | research@quoteddata.com | www.martenandco.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUUVARNWUUAAR
Date   Source Headline
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
4th Apr 20257:00 amRNSTransaction in Own Shares
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTotal Voting Rights
25th Mar 20253:16 pmRNSTransaction in Own Shares
24th Mar 20257:00 amRNSCapital Allocation Update
13th Mar 20257:00 amRNSFinal Results for the Year Ended 31 December 2024
26th Feb 20257:00 amRNSNotice of Results and Investor Presentation
5th Feb 20257:00 amRNSDirector Dealing
5th Feb 20257:00 amRNSDirector Dealing
3rd Feb 20257:00 amRNSDirector Dealing
29th Jan 20257:00 amRNSTrading update for the year ended 31 December 2024
20th Dec 202410:49 amRNSDirector Dealing
20th Dec 202410:48 amRNSDirector Dealing
19th Dec 20247:00 amRNSNorth Sails: Conversion of Equity
13th Dec 20247:00 amRNSDirector Dealing
13th Dec 20247:00 amRNSDirector Dealing
20th Nov 20247:00 amRNSOakley Capital invests in Konzept & Marketing
11th Nov 20247:00 amRNSHolding(s) in Company
8th Nov 20244:52 pmRNSHolding(s) in Company
6th Nov 20247:00 amRNSAppointment of Non-Executive Director
24th Oct 20247:00 amRNSOakley Capital agrees sale of Schülerhilfe to LLCP
23rd Oct 20247:00 amRNSTrading update for the 3 months ended 30 Sep 2024
21st Oct 20247:00 amRNSHolding(s) in Company
7th Oct 20247:00 amRNSOakley Capital invests in Assured Data Protection
12th Sep 20247:00 amRNSInterim Results for the 6 months ended 30 June 24
2nd Sep 20247:00 amRNSOakley agrees sale of Ocean to Lloyds Register
29th Aug 20247:00 amRNSNotice of Results and Investor Presentation
13th Aug 20247:00 amRNSDirector Dealing
26th Jul 20247:00 amRNSDirector Dealing
24th Jul 20247:00 amRNSTrading Update for the 6 Months ended 30 June 2024
17th Jul 20243:52 pmRNSHolding(s) in Company
28th Jun 20247:00 amRNSOakley agrees sale of its investment in idealista
11th Jun 20247:00 amRNSOakley to invest in cybersecurity firm I-TRACING
7th Jun 20247:00 amRNSDirector Dealing
3rd Jun 20243:43 pmRNSResult of AGM
28th May 20247:00 amRNSOakley Capital invests in ProductLife Group
14th May 20247:00 amRNSOakley Capital invests in vitroconnect
8th May 20247:00 amRNSNotice of Annual General Meeting
24th Apr 20247:00 amRNSTrading Update for the 3 months ended 31 March 24
2nd Apr 20244:17 pmRNSUpdate from QuotedData
27th Mar 20247:00 amRNSDirector Dealing
27th Mar 20247:00 amRNSDirector Dealing
26th Mar 20245:46 pmRNSHolding(s) in Company
26th Mar 20245:32 pmRNSHolding(s) in Company
18th Mar 20247:00 amRNSOakley Capital invests in Horizons Optical
15th Mar 20244:00 pmRNSQuotedData's Weekly News & Interview
14th Mar 20245:32 pmRNSDividend Declaration
14th Mar 20247:00 amRNSAnnual Results 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.